Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT0918 in mCRPC
NCT02826772Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Feb 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of proxalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Kintor Pharmaceutical Limited. Primary endpoints: Dose-Limiting Toxicities at 1 month and Maximum Tolerated Dose and Recommended Phase 2 Dose at 1 month. Started Feb 2016; status: completed.
02
Drugs
proxalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02826772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826772.